Yellow Fever Vaccine Information for Healthcare Providers

Announcement

Yellow fever vaccine recommendations

Yellow fever vaccine is recommended for people aged 9 months or older who are traveling to or living in areas at risk for yellow fever virus transmission in South America and Africa. Yellow fever vaccine may be required for entry into certain countries. Yellow fever vaccination requirements and recommendations for specific countries are available on the CDC Travelers' Health page.

Serious adverse events can occur following yellow fever vaccination. Therefore, persons should only be vaccinated if they are at risk of exposure to yellow fever virus or require proof of vaccination for country entry.

To minimize the risk of serious adverse events, healthcare providers should carefully observe the contraindications and consider the precautions about vaccination prior to vaccine administration (see below). A medical waiver can be given for persons with a precaution about or contraindication to vaccination. More information about medical waivers is available on the CDC Travelers' Health website.

For more information about the use of yellow fever vaccine in travelers or laboratory workers, see the Advisory Committee on Immunization Practice (ACIP) recommendations.

This vaccine is administered only at designated vaccination centers. For healthcare professionals who want to learn more about yellow fever disease and vaccine, a training module is available.

Yellow fever vaccine virus has been transmitted through blood transfusion and solid organ transplantation. Healthcare providers who administer yellow fever vaccine should inform patients of the need to defer blood donation for at least 2 weeks after receiving the vaccine.

Booster doses of the vaccine

In February 2015, the CDC Advisory Committee on Immunization Practices (ACIP) approved a new recommendation that a single dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers. The updated recommendations also identify specific groups of travelers who should receive additional doses and others for whom additional doses may be considered including:

• Woman who were pregnant when first vaccinated
• Persons who received a hematopoietic stem cell transplant following their last dose of yellow fever vaccine
• Persons who are HIV-infected
• Travelers who received yellow fever vaccine at least 10 years previously and who will be in a higher-risk setting based on season, location, activities, and duration of their travel
• Laboratory workers who routinely handle wild-type yellow fever virus

The official ACIP recommendations were published on June 19, 2015 (see Advisory Committee on Immunization Practice (ACIP) recommendations. All current ACIP yellow fever vaccine recommendations can be found on the ACIP website.

Because of the change to International Health Regulations no longer requiring booster doses, a completed International Certificate of Vaccination or Prophylaxis is now valid for the lifetime of the vaccinee. For more information on completing the International Certificate of Vaccination or Prophylaxis, visit the most recent version of CDC Yellow Book: Health Information for International Travel.

Contraindications

• Allergy to a vaccine component
• Aged younger than 6 months
• Symptomatic HIV infection or CD4+ T-lymphocytes <200/mm3 (<15% of total in children aged <6 years)
• Thymus disorder associated with abnormal immune function
• Primary immunodeficiencies
• Malignant neoplasms
• Transplantation
• Immunosuppressive and immunomodulatory therapies

Precautions

• Age 6 to 8 months
• Age 60 years or older
• Asymptomatic HIV infection and CD4+ T-lymphocytes 200 to 499/mm3 (15-24% of total in children younger than 6 years old)
• Pregnancy
• Breastfeeding

Reactions to yellow fever vaccine

Reactions to yellow fever vaccine are generally mild and include headaches, myalgias, and low-grade pyrexia. There have been reports of rare but serious events following yellow fever vaccination. These events include anaphylaxis, yellow fever vaccine-associated viscerotropic disease (YEL-AVD), and yellow fever vaccine-associated neurologic disease (YEL-AND). CDC can provide laboratory testing support for suspected YEL-AVD and YEL-AND cases.

Healthcare providers are encouraged to report all adverse events that might be caused by vaccination to the CDC/FDA Vaccine Adverse Events Reporting System (VAERS) by one of the following methods:

1. Submit a report online
2. Print a VAERS form and upload as instructed.

If you need further assistance with reporting to VAERS, please email info@VAERS.org or call 1-800-822-7967.

Additional vaccine information

• Yellow Fever Vaccine Recommendations of the Advisory Committee on Immunization Practices The 2010 recommendations include information on the epidemiology of YF, the safety profile of the vaccine, and health regulations related to the vaccine.
• Yellow fever vaccine booster doses: Recommendations of the Advisory Committee on Immunization Practices, 2015 Provides updated information on booster dose recommendations for YF vaccine.
• How Health Care Providers Can Become Certified to Administer Yellow Fever Vaccine
• Reporting Adverse Events Following Vaccination (Vaccine Adverse Events Reporting System)